GTR Test Accession:
Help
GTR000569040.5
NYS CLEP
CAP
Last updated in GTR: 2022-09-01
View version history
GTR000569040.5, last updated: 2022-09-01
GTR000569040.4, last updated: 2021-09-16
GTR000569040.3, last updated: 2021-09-15
GTR000569040.2, last updated: 2020-09-17
GTR000569040.1, last updated: 2019-09-27
Last annual review date for the lab: 2023-09-01
LinkOut
At a Glance
Test purpose:
Help
Drug Response;
Predictive;
Prognostic; ...
Conditions (1):
Help
Solid tumor
Genes (105):
Help
AKT1 (14q32.33), AKT2 (19q13.2), ALK (2p23.2-23.1), APC (5q22.2), AR (Xq12), ...
Methods (2):
Help
Molecular Genetics - Microsatellite instability testing (MSI): Next-Generation (NGS)/Massively parallel sequencing (MPS); ...
Target population: Help
Patients with advanced and metastatic solid cancers; Monitoring of a …
Clinical validity:
Help
Not provided
Clinical utility:
Help
Not provided
Ordering Information
Offered by:
Help
Test short name:
Help
xF
Specimen Source:
Help
- Cell-free DNA
- Peripheral (whole) blood
- Plasma
- View specimen requirements
Who can order: Help
- Health Care Provider
- Licensed Physician
- Nurse Practitioner
- Physician Assistant
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
To order the Tempus test:
1. Retrieve the Tempus xF collection kit. All required forms are contained in the box.
2. Complete the Requisition Form. A physician's signature is required.
4. Complete the Financial Assistance Form with the patient.
5. Fax the Requisition Form, Financial Assistance Form, and accompanying …
1. Retrieve the Tempus xF collection kit. All required forms are contained in the box.
2. Complete the Requisition Form. A physician's signature is required.
4. Complete the Financial Assistance Form with the patient.
5. Fax the Requisition Form, Financial Assistance Form, and accompanying …
Order URL
Test service:
Help
DNA sequencing for 105 genes
Comment: SNVs (105 genes), indels (105 genes), amplifications (6 genes), copy number loss (2 genes), gene rearrangements (7 genes)
Comment: SNVs (105 genes), indels (105 genes), amplifications (6 genes), copy number loss (2 genes), gene rearrangements (7 genes)
Test development:
Help
Test developed by laboratory (no manufacturer test name)
Informed consent required:
Help
Yes
Test strategy:
Help
The Tempus xF assay is a non-invasive, liquid biopsy panel designed to provide clinical decision support for solid tumors. It detects genomic alterations circulating in patients' peripheral blood, including single nucleotide variants (SNVs)/insertions and deletions (indels) in 105 genes, copy number gains (CNGs) in 6 genes, copy number losses (CNLs) …
View more
Pre-test genetic counseling required:
Help
No
Post-test genetic counseling required:
Help
No
Recommended fields not provided:
Test Order Code,
Lab contact for this test
Conditions
Help
Total conditions: 1
| Condition/Phenotype | Identifier |
|---|
Test Targets
Genes
Help
Total genes: 105
| Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
|---|
Methodology
Total methods: 2
Method Category
Help
Test method
Help
Instrument
Microsatellite instability testing (MSI)
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Illumina NovaSeq 6000 System
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Illumina NovaSeq 6000 System
Clinical Information
Test purpose:
Help
Drug Response;
Predictive;
Prognostic;
Therapeutic management
Target population:
Help
Patients with advanced and metastatic solid cancers; Monitoring of a patient’s response to treatment/ development of resistance;
Patients with tumors that are not accessible (e.g. tumor location, patient health); Patients with tissue specimens insufficient for sequencing (pathology rejection, insufficient quantity/ quality of DNA, etc.)
View citations (12)
- Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014;25(10):1959-1965. doi:10.1093/annonc/mdu288. Epub 2014 Jul 25. PMID: 25185240.
- Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discov. 2016;6(1):36-44. doi:10.1158/2159-8290.CD-15-0940. Epub 2015 Nov 06. PMID: 26546295.
- Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. Takai E, et al. World J Gastroenterol. 2016;22(38):8480-8488. doi:10.3748/wjg.v22.i38.8480. PMID: 27784960.
- Vendrell JA, Mau-Them FT, Béganton B, Godreuil S, Coopman P, Solassol J. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci. 2017;18(2). doi:10.3390/ijms18020264. Epub 2017 Jan 29. PMID: 28146051.
- Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Vidal J, et al. Ann Oncol. 2017;28(6):1325-1332. doi:10.1093/annonc/mdx125. PMID: 28419195.
- Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A. Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Res Treat. 2017;164(3):627-638. doi:10.1007/s10549-017-4257-x. Epub 2017 May 12. PMID: 28500398.
- Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Chung JH, et al. Ann Oncol. 2017;28(11):2866-2873. doi:10.1093/annonc/mdx490. PMID: 28945887.
- Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS. Liquid biopsy to monitor melanoma patients. J Dtsch Dermatol Ges. 2018;16(4):405-414. doi:10.1111/ddg.13461. Epub 2018 Mar 07. PMID: 29512873.
- Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019;156(1):108-118.e4. doi:10.1053/j.gastro.2018.09.022. Epub 2018 Sep 19. PMID: 30240661.
- Esposito Abate R, Pasquale R, Fenizia F, Rachiglio AM, Roma C, Bergantino F, Forgione L, Lambiase M, Sacco A, Piccirillo MC, Morabito A, Normanno N. The role of circulating free DNA in the management of NSCLC. Expert Rev Anticancer Ther. 2019;19(1):19-28. doi:10.1080/14737140.2019.1548938. Epub 2018 Nov 29. PMID: 30462523.
- Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Slifker M, Saltzberg PD, Bubes N, Anari FM, Kasireddy V, Varshavsky A, Liu Y, Ross EA, El-Deiry WS. Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Front Oncol. 2018;8:652. doi:10.3389/fonc.2018.00652. Epub 2019 Jan 17. PMID: 30705875.
- Scarlotta M, Simsek C, Kim AK. Liquid Biopsy in Solid Malignancy. Genet Test Mol Biomarkers. 2019;23(4):284-296. doi:10.1089/gtmb.2018.0237. Epub 2019 Mar 27. PMID: 30916594.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
Tempus uses an internally-built proprietary algorithm based on ACMG/AMP/ASCO guidelines for variant classification. Variants are reported in a tiered structure based on classification and therapeutic actionability. Variants with insufficient evidence to be classified as either pathogenic, likely pathogenic, likely benign or benign are classified as Variants of Uncertain Significance (VUS). … View more
Tempus uses an internally-built proprietary algorithm based on ACMG/AMP/ASCO guidelines for variant classification. Variants are reported in a tiered structure based on classification and therapeutic actionability. Variants with insufficient evidence to be classified as either pathogenic, likely pathogenic, likely benign or benign are classified as Variants of Uncertain Significance (VUS). … View more
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
No.
No.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
No.
No.
Sample reports:
Recommended fields not provided:
Clinical validity,
Clinical utility,
Is research allowed on the sample after clinical testing is complete?,
Sample positive report
Technical Information
Test Platform:
Other
Availability:
Help
Tests performed
Entire test performed in-house
Test performance comments
Tempus xF test is performed in its entirety at Tempus Labs, Chicago, IL.
Entire test performed in-house
Test performance comments
Tempus xF test is performed in its entirety at Tempus Labs, Chicago, IL.
Analytical Validity:
Help
The sensitivity of the Tempus xF panel is >99% for single nucleotide variants (SNVs) and copy number gains (CNGs) at ≥0.5% variant allele fraction (VAF), and >98% for insertions/deletions (indels) and >97% for rearrangements >0.5% VAF. BRCA1 and BRCA2 copy number loss is reported when detected. The specificity is >99.9% …
View more
Assay limitations:
Help
Not Intended For:
▪ Hematologic malignancies
▪ Early-stage (stage I/II) cancers
▪ Primary CNS malignancies
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
VUS:
Software used to interpret novel variations
Help
Not provided
Laboratory's policy on reporting novel variations Help
Tempus reports novel variants if detected somatically and classified as pathogenic, likely pathogenic, or VUS.
Not provided
Laboratory's policy on reporting novel variations Help
Tempus reports novel variants if detected somatically and classified as pathogenic, likely pathogenic, or VUS.
Recommended fields not provided:
Test Confirmation,
Description of internal test validation method,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Category:
FDA exercises enforcement discretion
NYS CLEP Approval:
Help
Number:
63002
Status: Approved
Status: Approved
Additional Information
Reviews:
Clinical resources:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.